Drug & intervention
ranolazine
RxCUI 35829
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
Ranolazine
Ranolazine, sold under the brand name Ranexa among others, is a medication used to treat heart related chest pain. Typically it is used together with other medications when those are insufficient. Therapeutic benefits appear smaller in females than males. It is taken by mouth. Common side effects include constipation, headache, nausea, and dizziness. Serious side effects may include QT prolongation. Ranolazine is contraindicated (not recommended) in those with liver cirrhosis. How it works is not clear but may involve adenosine triphosphate. Ranolazine was approved for medical use in the United States in 2006. In 2022, it was the 232nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
23 shownFeasibility Trial for a Right Ventricular Failure Platform TrialNCT06570473 · 2025-07-15
RECRUITINGDoes Ranolazine Decrease Biomarkers of Myocardial Damage in DiabeticsNCT02611596 · 2016-11-01
WITHDRAWNTargeting Right Ventricle in Pulmonary Hypertension GileadNCT02829034 · 2016-07-01
COMPLETEDA Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor RanolazineNCT01992016 · 2014-04-07
COMPLETEDTargeting the Right Ventricle in Pulmonary HypertensionNCT01839110 · 2013-07-01
COMPLETEDThe Use of Ranolazine for Atrial Fibrillation and Diastolic Heart FailureNCT01887353 · 2013-06-01
TERMINATEDEffects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CADNCT01754259 · 2013-04-01
COMPLETEDA Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.NCT01843127 · 2013-04-01
COMPLETEDA Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin AloneNCT01555164 · 2012-06-01
COMPLETEDSingle Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mgNCT01546558 · 2012-02-01
COMPLETEDSingle Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With RanolazineNCT01546597 · 2012-02-01
COMPLETEDRanolazine When Added to Glimepiride in Subjects With Type 2 Diabetes MellitusNCT01494987 · 2012-01-01
COMPLETEDRanolazine Monotherapy in Subjects With Type 2 Diabetes MellitusNCT01472185 · 2011-11-01
COMPLETEDRanolazine Implantable Cardioverter-Defibrillator TrialNCT01215253 · 2011-09-01
COMPLETEDType 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable AnginaNCT01425359 · 2011-09-01
COMPLETEDA Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial HypertensionNCT01757808 · 2011-08-01
COMPLETEDStudy of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular DysfunctionNCT02133352 · 2011-07-01
COMPLETEDA Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)NCT01334203 · 2011-05-01
WITHDRAWNThe Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection FractionNCT01505179 · 2011-02-01
COMPLETEDExploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic TherapyNCT01163721 · 2010-06-01
COMPLETEDRanolazine and Pulmonary HypertensionNCT01174173 · 2010-06-01
COMPLETEDRanolazine in Diastolic Heart FailureNCT01163734 · 2010-04-01
COMPLETEDEffect of Ranolazine on Echocardiographic Indices of Diastolic DysfunctionNCT00574756 · 2007-12-01
TERMINATEDConditions being studied
Type 2 Diabetes Mellitus8Pulmonary Hypertension4Coronary Artery Disease3Angina2Angina Pectoris2Diastolic Heart Failure2Heart Failure2Pulmonary Arterial Hypertension2Adenocarcinoma of the Prostate1Atrial Fibrillation1Bone Metastases1Diabetes Mellitus, Type 21Diabetes, Type I1Diabetes, Type II1Diastolic Left Ventricular Dysfunction1Echocardiography1Heart Failure With Preserved Ejection Fraction1Ischemic Cardiomyopathy1Nonischemic Cardiomyopathy1Ranolazine1
Research locations
ChicagoIllinois, United States6BostonMassachusetts, United States5HoustonTexas, United States5Los AngelesCalifornia, United States5MiamiFlorida, United States5OrlandoFlorida, United States5DallasTexas, United States4KyivUkraine4MoscowRussia4NovosibirskRussia4OdesaUkraine4SacramentoCalifornia, United States4
Leading sponsors
Gilead Sciences10University of California, San Diego2University of Pennsylvania2Boston University1Brigham and Women's Hospital1Intermountain Health Care, Inc.1Northwestern University1University of Alberta1University of Chicago1University of Colorado, Denver1University of Rochester1Walter Reed National Military Medical Center1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.